For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The regional market for hemostats and tissue sealants has been estimated to burgeon at 9.65% CAGR and is expected to reach $ xx million by 2027. The primary driver for such growth is due to the improvements in government funding for subsidizing to develop and improvise new surgical sealants and hemostats.
China, India, Japan, Australia, South Korea & countries from the Rest of Asia Pacific region are considered for this market study. The Asia Pacific market is expected to witness an exponential growth for the hemostasis and sealing agents since there have been higher numbers of typical surgeries performed in hospital settings and establishments of research societies that are fostering knowledge about clinical trials and other scientific information about hemostasis and thrombosis. Also, Australia has the fastest growing market for hemostats and tissue sealants in the APAC region. This is due to the increase in population growth and healthcare expenditure.
The competing corporations involved with the hemostat and tissue sealant market are CSL Behring, Advanced Medical Solutions (AMS) Group PLC, Cryolife Inc., Baxter International Inc., B.Braun Melsungen AG, Cohera Medical Inc., Hyperbranch Medical Technology, Inc. (Acquired by Stryker), Integra Lifesciences Corp., Johnson & Johnson, Medtronic PLC, Pfizer, Inc., Smith & Nephew PLC and C.R. Bard, Inc.